Genfit Names Carol Addy to Chief Medical Officer Role

Carol Addy has been appointed chief medical officer of France-based Genfit (NASDAQ: [[ticker:GNFT]]). She will be based at the company’s Cambridge, MA, office. Addy, an endocrinologist, was most recently the chief medical officer of Merck (NYSE: [[ticker:MRK]]) subsidiary Health Management Resources. Genfit’s lead drug candidate, elafibranor, is currently in late-stage testing as a treatment for the liver disease nonalcoholic steatohepatitis. Preliminary data are expected in the first quarter of next year.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan